Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review

Author(s): Alessandra Bearz*, Massimiliano Berretta, Umberto Tirelli.

Journal Name: Current Cancer Drug Targets

Volume 18 , Issue 5 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Graphical Abstract:


Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm, improvement of progression free survival and overall survival, but also higher costs for health systems or health insurances.

Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according to their clinically meaningful outcome criteria and their cost impact.

Keywords: NSCLC, target agents, therapy, cost, chemotherapy, metastases, prognoses.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Page: [405 - 409]
Pages: 5
DOI: 10.2174/1568009617666170206112408
Price: $65

Article Metrics

PDF: 32